Peripartum cardiomyopathy: Euro Observational Research Program

[1]  K. Sliwa,et al.  Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. , 2014, European heart journal.

[2]  P. Ponikowski,et al.  EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM , 2014, European journal of heart failure.

[3]  N. Bello,et al.  The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. , 2013, Journal of the American College of Cardiology.

[4]  K. Sliwa,et al.  Peripartum cardiomyopathy: update 2012 , 2013, Current opinion in critical care.

[5]  K. Sliwa,et al.  MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. , 2013, The Journal of clinical investigation.

[6]  C. Angermann,et al.  Peripartum cardiomyopathy. An update. , 2012, Minerva ginecologica.

[7]  John Mitchell,et al.  Cardiac Angiogenic Imbalance Leads to Peri-partum Cardiomyopathy , 2012, Nature.

[8]  B. Horne,et al.  Genome-Wide Significance and Replication of the Chromosome 12p11.22 Locus Near the PTHLH Gene for Peripartum Cardiomyopathy , 2011, Circulation. Cardiovascular genetics.

[9]  N. de Jonge,et al.  Peripartum cardiomyopathy: the need for a national database , 2011, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[10]  K. Sliwa,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy , 2010, European journal of heart failure.

[11]  W. Paulus,et al.  Peripartum Cardiomyopathy as a Part of Familial Dilated Cardiomyopathy , 2010, Circulation.

[12]  K. Sliwa,et al.  Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum Cardiomyopathy: A Proof-of-Concept Pilot Study , 2010, Circulation.

[13]  K. Sliwa,et al.  A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum Cardiomyopathy , 2007, Cell.

[14]  C. Clapp,et al.  Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. , 2002, The Journal of endocrinology.

[15]  Y. Fujio,et al.  Activation of Signal Transducer and Activator of Transcription 3 Protects Cardiomyocytes from Hypoxia/Reoxygenation-Induced Oxidative Stress Through the Upregulation of Manganese Superoxide Dismutase , 2001, Circulation.

[16]  T. Wagner,et al.  Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells. , 2000, International journal of oncology.

[17]  L. Baxter.  Documenting nurse-midwifery outcomes. The need for a national database. , 1986, Journal of nurse-midwifery.

[18]  S. Jayalakshmi,et al.  Peripartum cardiomyopathy. , 1980, Journal of the Indian Medical Association.